



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
C07B 59/00 (2006.01) *C07D 519/00* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/EP2011/052353

(22) International Filing Date:

17 February 2011 (17.02.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/306,248 19 February 2010 (19.02.2010) US
 61/429,372 3 January 2011 (03.01.2011) US
 61/429,997 5 January 2011 (05.01.2011) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRAIN, Christopher, Thomas** [GB/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **CHO, Young Shin** [KR/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **GIRALDES, John, William** [US/US]; Novartis Institutes for BioMedical, Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **LAGU, Bharat** [US/US]; Novartis Institutes for BioMed-

ical, Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **LEVELL, Julian** [GB/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **LUZZIO, Michael** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **PEREZ, Lawrence, Blas** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **WANG, Yaping** [CN/US]; 96 Patch Hill, Boxborough, Massachusetts 01719 (US). **YANG, Fan** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).


(74) Agent: **STRANG, Andrea**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6



(57) Abstract: The invention is directed to novel pyrrolopyrimidine compounds of formula (I) wherein R^1 , R^{2Y} , R^4 , R^8 - R^{11} , A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.



GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*